Search Login Register
Busulfan
(Busulfex)
Summary
Description:
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Also Known As:
Busulfex; Myleran; Busulfan Wellcome; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan Show All >>
Networked: 1454
relevant articles (121 outcomes,
164 trials/studies)
for this Drug
Key Diseases for which Busulfan is
Relevant
-
Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
:
34 outcomes 12 studies in 115 results
-
BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
:
20 outcomes 19 studies in 233 results
-
Leukemia
:
14 outcomes 17 studies in 142 results
-
Myelodysplastic Syndromes (Myelodysplastic Syndrome)
:
7 outcomes 4 studies in 54 results
-
Hematologic Neoplasms (Hematological Malignancy)
:
5 outcomes 15 studies in 78 results
Show All >>
Drugs Related to Busulfan
-
Cyclophosphamide (Cytoxan)
-
fludarabine
-
Melphalan (Alkeran)
-
Thiotepa (Triethylenethiophosphoramide)
-
Etoposide (VP 16)
-
Hydroxyurea (Hydrea)
-
Antilymphocyte Serum (Anti-Thymocyte Globulin)
-
Interferon-alpha (Interferon Alfa)
-
thymoglobulin
-
Interferons
Show All >>
Therapies Related to Busulfan
-
Hematopoietic Stem Cell Transplantation
-
Transplantation (Transplant Recipients)
-
Drug Therapy (Chemotherapy)
-
Stem Cell Transplantation
-
Bone Marrow Transplantation (Transplantation, Bone Marrow)
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.